Beijing ShuRui Technology Co.Ltd. (hereinafter referred to as "ShuRui") announced its completion of C3 round funding with hundreds of millions of yuan. The investment was led by Loyal Valley Capital, participated by DNV Capital, NNFE, and Sanya Cuihu, and received full support from previous shareholders such as V Star Capital and State Development & Investment Corp（SDIC）.
The funds will be used to promote the clinical trials and ShuRui's existing flagship products in China and abroad and R&D on new products, which will fully enhance ShuRui's competitive advantages in the sector of surgical robots.
Founded in 2014, ShuRui is a high-tech enterprise dedicated to independent research and development, production, and sales of single/multi-port universal minimally invasive endoscopic surgical robot systems. The company's founder, Professor Xu Kai, graduated from Columbia University in the United States and studied under "the father of medical robotics," Professor Russell Taylor.
Since its establishment, the company has focused on building core independent intellectual property rights and key technologies throughout the chain. Its main product, the endoscope surgical system (SR-ENS-600), has been approved to enter the special review program for innovative medical devices by the National Medical Products Administration's medical device evaluation center in 2020. With the innovative design of the "dual-continuum mechanism," the product carries a highly deformable surgical arm with agile and precise movement, and its comprehensive performance can rival the leading international single-port surgical robots, breaking foreign technological monopolies that have lasted for years.
ShuRui has submitted more than 500 patent applications globally, with 147 patents in China and 40 overseas. Its products are mainly used in urology, gynecology, cardiothoracic surgery, general surgery, and other departments, providing minimally invasive solutions for cross-departmental indications.
It is reported that ShuRui has completed multiple rounds of financing before the C3 round, including A and B rounds led by well-known domestic investment institutions. The successful completion of this C3 round not only demonstrates the market's high recognition of ShuRui but also injects new momentum into its future development.
The funding will provide ample capital support for ShuRui's future development, while also reflecting the market's high expectations for its prospects. With deepening research in high-tech fields, ShuRui is expected to occupy a larger market share in the future competition.
As a high-tech enterprise capable of independently developing, manufacturing, and selling third-generation minimally invasive surgical robot systems, Aurora Surgical Robotics uses a single system to achieve the application of both single-hole and multi-hole laparoscopic surgery in multiple departments, providing hospitals with a complete solution for "preoperative planning, intraoperative operation, and postoperative management" for fully intelligent surgery, and ultimately promoting the continuous development of human health and hygiene.
The Aurora Robotics team currently has dozens of senior R&D engineers, many of whom come from well-known medical equipment and diagnostic equipment companies, and have degrees from leading engineering schools such as the University of Michigan, Shanghai Jiao Tong University, and Huazhong University of Science and Technology, with extensive experience in the design and development of mechatronic robots and medical devices.
At present, the Aurora research and development team is pushing ahead with clinical research on modular laparoscopic surgery robot products for single and multiple holes. It is expected that after the product is successfully launched, it will break the market monopoly of the Da Vinci surgical robot in the United States, promote the further application of surgical robots, meet the increasing demand of people for high-end precision medical care, and have the potential to export original technology to European and American markets, striving to become a technological pioneer and market leader in the global third-generation surgical robot field.
The global laparoscopic surgery robot system track is undergoing rapid development, with major competitors including Intuitive Surgical（CHINESE:美敦力）, Medtronic（CHINESE:迈瑞医疗）, and others, continuously launching new laparoscopic surgery robot systems to meet the medical market's demand for more delicate and accurate procedures. Currently, the global laparoscopic surgery robot system market is showing a trend of rapid growth, especially in developed countries such as the United States and Europe, where the market share is relatively high. At the same time, the Asia-Pacific region is also gradually becoming an important market in this field. It is expected that by 2025, the global market for laparoscopic surgery robot systems will exceed USD 3.5 billion. In addition to traditional surgical robot systems, there have been some innovative products in recent years. For example, Verb Surgical's "digital operating room" can achieve wireless connectivity and big data analysis, thereby improving the efficiency and safety of surgery. In addition, many start-up companies are emerging, hoping to occupy a place in this field.
Currently, the global laparoscopic surgery robot system track will continue to maintain high-speed development. The continuous innovation of technology and the increasing demand from the market will intensify competition in this field, as well as promote the continuous improvement of the functions and performance of surgical robot systems to meet the medical industry's demand for higher quality and safer surgery.
At this critical stage, the ESG2023 "the US Sub-Forum" will be held in Shenzhen on June 2, 2023. EqualOcean will invite the representatives of academic institutions and investment institutions, as well as company leaders, from the International Studies Institute of Fudan University, Sun Yat-sen University, Jinan University School of International Relations, Gaorong Capital, Vision Plus Capital, FreeS Fund, ZWC Partners, Source Code Capital, Niu Technologies, TikTok, SHEIN, NEIWAI, miHoYo, Tuya, MINISO, Dreame, Ecovacs, WYBOTICS, Lifen, and UniUni.EqualOcean analysts will also release the US Report 2023 at the US Sub-Forum, summarizing business opportunities and best practices for expanding into the US market in the new stage. Click the link to apply and scan the QR code below to learn more about ESG2023.
